The criteria of primary systemic vasculitis proposed by the European Medicines Agency (EMEA) Tucidinostat solubility dmso algorithm was employed for enrollment [2]. This study was registered on the University Hospital Medical Information Network Clinical Trials Registry (UMIN000001648). Patients were evaluated at 3, 6, 12, 18, and 24 months and at relapse. The primary outcome measure was remission rate, and secondary outcome measures were survival rate, renal survival rate, and relapse. In total, 156 AAV patients were enrolled; all FAK inhibitor observations were completed by March 2013. Final data collection is in progress. Co-RemIT-JAV Based
on our retrospective study elucidating the risk factors for relapse in patients with myeloperoxidase (MPO)-ANCA positive MPA [1], we are conducting an observational cohort study of remission maintenance therapy in Japanese AAV patients (Co-RemIT-JAV) (UMIN000006373). The study objective is to clarify the safety and efficacy of remission maintenance therapy in Japanese AAV patients. At present, 60 of 156 AAV patients registered in RemIT-JAV were extended to follow up every 6 months
up to 48 months after the end of follow-up for RemIT-JAV. The primary outcome measure is relapse rate, and secondary outcome measures are survival and MK-8931 price renal survival rates. The observation stage will be completed by March 2015; data collection is currently in progress. RemIT-JAV-RPGN After RemIT-JAV, we conducted a nationwide, prospective cohort study of remission induction therapy in Japanese patients with ANCA-associated vasculitides and rapidly progressive glomerulonephritis (RemIT-JAV-RPGN) (UMIN000005136) including 47 university hospitals and referring hospitals. Enrollment of consecutive patients
newly diagnosed with AAV began in April 2011 and will continue till December 2013. The primary and some secondary outcome measures are the same as those in RemIT-JAV, but pathological analysis of renal involvement and radiological analysis of pulmonary involvement will be added. Further, CYTH4 biological samples (serum, urine, and total RNA) will be collected and offered to the Basic and Pathological Research Subcommittee for Research for identifying candidate biomarkers. Prospective cohort study for large-sized vessel vasculitis We also conducted a nationwide Japanese prospective observational study on the current state and efficacy of therapeutics for large-vessel vasculitis (UMIN000010414). The subjects included patients newly diagnosed with Takayasu arteritis and giant cell arteritis. The study objective was to clarify the current state and efficacy of therapeutics for large-vessel vasculitis in Japan and to evaluate the utility of the current diagnostic criteria and classification for large-vessel vasculitis. The primary outcome measure of this study is remission rate.